CFTR gene delivery to human airway epithelia using parainfluenza virus 5 amplifying virus-like particles.
A new virus-based system delivers cystic fibrosis gene therapy more effectively than previous approaches, potentially helping patients without drug options.
Researchers from Iowa developed a novel parainfluenza virus 5 (PIV5) amplifying virus-like particle system to deliver the CFTR gene to human bronchial and nasal airway epithelia, achieving robust transduction of primary cultures. This novel vector platform addresses key limitations of existing CF gene therapy approaches including AAV cargo capacity and adenoviral immunogenicity, potentially expanding gene therapy options for patients who cannot access CFTR modulators.
What the study was
- Study design
- Preclinical translational study (ex vivo human airway)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Mol Ther Nucleic Acids
Why it surfaced
Novel VLP vector approach for CF gene therapy; ex vivo human airway primary culture system is high-translatability preclinical evidence; published in Mol Ther Nucleic Acids (top gene therapy journal); addresses patients not responsive to modulator therapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.